Patents Assigned to Hoffmann-La Roche Inc.
  • Compounds for treating spinal muscular atrophy
    Patent number: 11827646
    Abstract: The present invention provides compounds of formula (I) wherein A, R1, R2 and R3 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments.
    Type: Grant
    Filed: November 16, 2020
    Date of Patent: November 28, 2023
    Assignees: Hoffmann-La Roche Inc., PTC Therapeutics, Inc.
    Inventors: Hasane Ratni, Luke Green, Marla L. Weetall, Nikolai A. Naryshkin
  • Antibodies binding to NKG2D
    Patent number: 11827711
    Abstract: The present invention generally relates to antibodies that bind to NKG2D, including multispecific antigen binding molecules e.g. for activation of T cells and/or NK cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Grant
    Filed: July 14, 2020
    Date of Patent: November 28, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Stefan Dengl, Guy Georges, Ralf Hosse, Inja Waldhauer, Christian Klein, Pablo Umana
  • ANTIBODY THAT BINDS TO VEGF-A AND ANG2 AND METHODS OF USE
    Publication number: 20230374119
    Abstract: The present invention relates to anti-VEGF-A/anti-ANG2 antibodies, e.g. in the form of a bispecific Fab fragment, and methods of using the same.
    Type: Application
    Filed: June 22, 2023
    Publication date: November 23, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Roland Beckmann, Sebastian Fenn, Guido Hartmann, Sabine lmhof-Jung, Kristian Hobolt-Jensen, Joerg Moelleken, Michael Molhoj, Christian Schantz, Janina Speck, Christoph UlImer, Barbara Weiser
  • CRISPR/Cas9 MULTIPLEX KNOCKOUT OF HOST CELL PROTEINS
    Publication number: 20230374497
    Abstract: The present disclosure relates to modified mammalian cells having reduced or eliminated expression of certain cellular proteins, CRISPR/Cas9 multiplex knockout strategies for making such cells, and methods of using such cells, e.g., in the context of cell-based therapy or as host cells in the production of a product of interest.
    Type: Application
    Filed: February 28, 2023
    Publication date: November 23, 2023
    Applicants: GENENTECH, INC., HOFFMANN-LA ROCHE INC.
    Inventors: Amy SHEN, Inn Huam Yuk, Peggy Wai No Ko, Shahram Misaghi, Simon Thomas Auslaender, Midori Greenwood-Goodwin, Michael Wilson Laird, Benedikt Alois Claudius Oswald
  • HETEROARYL-SUBSTITUTED IMIDAZOLE DERIVATIVES
    Publication number: 20230373978
    Abstract: The invention provides novel heteroaryl-substituted imidazole derivatives having the general formula (I), and pharmaceutically acceptable salts thereof, wherein A and R1 to R6 are as described herein: Further provided are pharmaceutical compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as medicaments, in particular methods of using the compounds as antibiotics for the treatment or prevention of bacterial infections and resulting diseases.
    Type: Application
    Filed: August 1, 2023
    Publication date: November 23, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Christian LERNER, Mingming LI, Yongqiang LIU, Jianhua WANG, Min WANG, Yongguang WANG, Song YANG, Chengang ZHOU
  • CGAS INHIBITING TRIAZOLOPYRIMIDONE DERIVATIVES
    Publication number: 20230374014
    Abstract: The invention relates to a compound of formula (I), wherein R1-R3 and A1-A3 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: May 18, 2021
    Publication date: November 23, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Guido GALLEY, Katrin GROEBKE ZBINDEN, Wolfgang GUBA, Daniel HUNZIKER
  • MACHINE-LEARNING MODEL FOR GENERATING HEMOPHILIA PERTINENT PREDICTIONS USING SENSOR DATA
    Publication number: 20230377747
    Abstract: Disclosed are systems and methods for building and using a machine-learning model to facilitate intelligent selection of treatment strategies for subjects suffering from hemophilia. Sensor data (e.g., that characterizes movement of or a physiological characteristic of particular a subject) can be used as an input to a machine-learning model workflow. The sensor data may affect a model selection, model configuration, model result, pre-processing and/or post-processing. A result of the workflow may inform or influence a treatment selection, treatment schedule, treatment dosage and/or activity recommendation for the particular subject.
    Type: Application
    Filed: September 29, 2021
    Publication date: November 23, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Silvia Elena MOLERO LEON, Hélène Jeanne SAHRI, Turap TASOGLU
  • Peptide macrocycles against
    Patent number: 11819532
    Abstract: The present invention provides compounds of formula (I) wherein X1, X2, R1 to R6 and A are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments for the treatment of diseases and infections caused by bacteria.
    Type: Grant
    Filed: April 19, 2019
    Date of Patent: November 21, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Konrad Bleicher, Daniella Cheang, Patrick Di Giorgio, Patrizio Mattei, Petra Schmitz, Theodor Stoll
  • Assay for determining antibody or ligand binding and function
    Patent number: 11821897
    Abstract: The present invention relates to a new cell based assay for determining antibody or ligand binding and function using lipid-like compounds capable of spontaneous integration into cell membranes.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: November 21, 2023
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Regula Buser, Sandra Grau-Richards, Virginie Steinhart
  • Heterocyclic compounds
    Patent number: 11814375
    Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein A, B, L1, X, m, n, and R1 to R7 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
    Type: Grant
    Filed: September 10, 2020
    Date of Patent: November 14, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Joerg Benz, Luca Gobbi, Uwe Grether, Katrin Groebke Zbinden, Benoit Hornsperger, Carsten Kroll, Bernd Kuhn, Rainer E. Martin, Fionn O'Hara, Bernd Puellmann, Hans Richter, Martin Ritter
  • IMPROVED ANTIGEN BINDING RECEPTORS
    Publication number: 20230357431
    Abstract: The present invention generally relates to activatable antigen binding receptors capable of specific binding to a mutated Fc domain. The antigen binding receptors of the invention are activatable through (a) protease(s). After activation, the antigen binding receptors are targeted to tumor cells by specifically binding to/interacting with the mutated Fc domain of therapeutic antibodies. The invention also relates to transduced immune cells expressing the antigen binding receptors of the invention and/or nucleic acid molecules encoding the antigen binding receptors of the present invention. Further provided are kits comprising such cells and/or nucleic acid molecules in combination with tumor targeting antibodies comprising a mutated Fc domain.
    Type: Application
    Filed: April 27, 2023
    Publication date: November 9, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Diana DAROWSKI, Martina GEIGER, Christian KLEIN
  • METHOD FOR THE DETERMINATION OF HYDROLYTIC ACTIVITY
    Publication number: 20230358748
    Abstract: Herein is reported a method for determining the presence of hydrolase activity in a sample by incubating the sample in a buffered solution, which comprises an artificial hydrolase substrate that comprises an ester bond covalently linking an alcohol residue, which is conjugated to a label for removal, and a carboxylic acid residue, which is conjugated to a capture and detection label, as well as bovine serum albumin, and thereafter determining or quantifying, respectively, the released carboxylic acid in the free alcohol depleted incubation mixture.
    Type: Application
    Filed: December 16, 2022
    Publication date: November 9, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Franziska EDELMANN, Roberto FALKENSTEIN, Tobias GRAF, Sanjay GUPTA, Lars HILLRINGHAUS, Tarik Ali KHAN, Michael LEISS, Thomas MEIER, Michael WIEDMANN
  • COMBINATION THERAPY WITH TARGETED 4-1BB (CD137) AGONISTS
    Publication number: 20230357397
    Abstract: The present invention relates to combination therapies employing tumor targeted anti-CD3 bispecific antibodies and/or agents blocking PD-L1/PD-1 interaction in combination with 4-1BB (CD137) agonists, in particular 4-1BBL trimer containing antigen binding molecules, the use of these combination therapies for the treatment of cancer and methods of using the combination therapies.
    Type: Application
    Filed: February 9, 2023
    Publication date: November 9, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marina BACAC, Christina CLAUS, Claudia FERRARA KOLLER, Christian KLEIN, Sabine LANG, Viktor LEVITSKI, Pablo UMAÑA
  • IN SILICO PREDICTIONS OF AMYLOID-RELATED IMAGING ABNORMALITIES
    Publication number: 20230360721
    Abstract: A dosage of an active ingredient in a treatment that is being provided to or that is being considered for provision to a subject is identified. A level of local amyloid beta is predicted based on the dosage of the active ingredient. A severity of amyloid-related imaging abnormalities (ARIA) manifested as hyperintensities on T2-weighted fluid attenuated inversion recovery (FLAIR) images (ARIA-E) is predicted based on the predicted removal of local amyloid beta, where predicting severity of ARIA-E includes predicting an extent of vascular wall disturbance. A result corresponding to the predicted ARIA-E severity is output.
    Type: Application
    Filed: April 27, 2023
    Publication date: November 9, 2023
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Roxana Aldea, Hans Peter Grimm, Norman A. Mazer
  • COMBINATION THERAPY OF TUMOR TARGETED ICOS AGONISTS WITH T-CELL BISPECIFIC MOLECULES
    Publication number: 20230355754
    Abstract: The present invention relates to agonistic ICOS-binding molecules comprising at least one antigen binding domain that binds to a tumor-associated antigen and their use in combination with T-cell bispecific molecules in the treatment of cancer, the agonistic ICOS-binding molecules as such, pharmaceutical compositions comprising these molecules, and methods of using the same.
    Type: Application
    Filed: March 6, 2023
    Publication date: November 9, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marina BACAC, Tanja FAUTI, Christian KLEIN, Johannes SAM, Pablo UMANA, Ramona MURR, Joerg ZIELONKA, Lucas HABEGGER
  • Benzimidazole derivatives
    Publication number: 20230348398
    Abstract: The invention relates to a compound of formula (I) wherein R1-R4 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: April 14, 2021
    Publication date: November 2, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Guido GALLEY, Katrin GROEBKE ZBINDEN, Daniel HUNZIKER, Wolfgang GUBA, Stefan BERCHTOLD, Danny KRUMM, Daniela KRUMMENACHER, Manuel HILBERT
  • ALTERNATIVE SURFACTANTS AS STABILIZERS FOR THERAPEUTIC PROTEIN FORMULATIONS
    Publication number: 20230346931
    Abstract: The present invention relates to novel liquid pharmaceutical compositions comprising proteins, preferably antibodies as defined herein together with one or more surfactants selected from TPGS, PVA, T1107, Px338, Px407, TMN-6, 15-S-15, Chol-PEG, and SL.
    Type: Application
    Filed: January 5, 2023
    Publication date: November 2, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Marc HEITZ, Tarik KHAN, Hannah Sophia KIENTZ, Claudia MUELLER, Janina Michelle PFAFF
  • Heterocyclic compounds as monoacylglycerol lipase inhibitors
    Patent number: 11802133
    Abstract: The invention provides new heterocyclic compounds having the general formula (I) wherein A, L, X, m, n, R1 and R2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
    Type: Grant
    Filed: May 20, 2022
    Date of Patent: October 31, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Charles Bell, Joerg Benz, Luca Gobbi, Uwe Grether, Katrin Groebke Zbinden, Benoit Hornsperger, Buelent Kocer, Carsten Kroll, Bernd Kuhn, Marius Daniel Rinaldo Lutz, Fionn O'Hara, Hans Richter, Martin Ritter, Didier Rombach, Martin Kuratli
  • NEW TREATMENT OF SMA
    Publication number: 20230338382
    Abstract: The present invention relates to 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one for use in the treatment of spinal muscular atrophy (SMA), its pharmaceutical composition to be used in the treatment of SMA, its methods of treatment thereof.
    Type: Application
    Filed: December 5, 2022
    Publication date: October 26, 2023
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Jean-Paul Pfefen, Heidemarie Kletzl, Lutz Mueller
  • Display screen or portion thereof with graphical user interface
    Patent number: D1004611
    Type: Grant
    Filed: November 17, 2020
    Date of Patent: November 14, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Silvia Elena Molero Leon, Hélène Jeanne Sahri, Turap Tasoglu